MZ schreef op 21 januari 2018 18:06:
Zo, alle posts van dit weekend eens doorgenomen op de zondagmiddag.
De euforie spat van het forum af en terecht! Echter komen er wel heel ongeloofwaardige koersen voorbij, laat je niet gek maken en trek je eigen plan.
Ook ik denk dat het nog (veel) hoger kan, maar koersen van 50+ euro slaat op dit moment nergens op natuurlijk.
Waar kan wel nog verdere waarde gecreëerd worden naast de omzet uit Ruconest?
Ik verwacht heel veel van het
transgene productie platform van pharming.
Quote uit van Leeuwenhoek rapport:"
Pharming's technologies include innovative platforms for the production of protein therapeutics,
as well as technology and processes for the purification and formulation of these products. It has
developed methods and technology for breeding transgenic animals for subsequent isolation and purification of protein products from the milk which offers the ability to produce complex
proteins at high volume and low cost and for a variety of applications. Conventional methods used
for producing recombinant proteins, such as cell culture using animal, bacterial, or yeast cells, are
often disadvantaged in that they are expensive for large-scale production, are immunogenetic or
are unable to produce proteins with required complex posttranscriptional modifications. In contrast
Transgenic technology, using either microinjection or nuclear transfer, enables the expression of
human proteins in a system that is more reliable and relatively easy to scale up and can be
established and operated at a relatively low cost.
Besides lower costs, transgenic technology provides an ideal route for bulk production since very
high expression levels of fully bioactive protein are obtained. However, one has to bear in mind
that the purification of proteins from milk under GMP conditions is as costly as with other
production methods.
Rabbits produce significant quantities of milk, in the range of 100-250ml/day (approx 10-15l of milk
per rabbit per year). Their prolific nature reduces the time required to establish a transgenic line
and so accelerates time-to-market for the recombinant protein. Large numbers of genetically
identical transgenic rabbits can be generated in a relatively short time.
Dit is een nieuwe veelbelovende techniek waarvan pharming de rechten heeft tot en met 2026!" The most effective form of defense for Pharming’s lead product RUCONEST® is the data exclusivity rights it has in the major US market, which last until 2026. While not a patent, this prevents another party from developing its own product and
referencing the trials that Pharming has completed as evidence for its own product. In practice, this
means that new entrants must develop their own recombinant product and must test it in the clinic
as if RUCONEST® did not exist. Pharming’s data exclusivity in respect of such trials lasts until 2026
in the US, providing strong protection in that market. Pharming’s new products in Pompe disease
and Fabry disease will benefit from similar rights once they have completed their own clinical trial
programs.